Mechanism of Action: Cytochrome P450 3A4 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Cytochrome P450 3A4 Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-003 | Jul 9, 2010 | AB | RX | Yes | No | 9,006,224 | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-003 | Jul 9, 2010 | AB | RX | Yes | No | 8,410,131*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-001 | Mar 30, 2009 | AB | RX | Yes | Yes | 9,006,224 | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-001 | Mar 30, 2009 | AB | RX | Yes | Yes | 8,410,131*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Novartis | AFINITOR | everolimus | TABLET;ORAL | 022334-004 | Mar 30, 2012 | AB | RX | Yes | No | 9,006,224 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
